Joshua K. Sabari, MD, reviews the case of a 73-year-old with EGFR+ non–small cell lung cancer and provides comprehensive insights on the evolving treatment landscape.
EP. 1: Patient Profile: A 73-Year-Old Man with EGFR+ NSCLC
Joshua K. Sabari, MD, reviews the patient profile of a 73-year-old patient with EGFR+ non–small cell lung cancer.
EP. 2: Overview of Treatment Options for EGFR+ NSCLC
A medical oncologist provides an overview of treatment options available for patients with EGFR+ non–small cell lung cancer.
EP. 3: EGFR+ NSCLC: Recent Data From FLAURA2
Joshua K. Sabari, MD, reviews clinical trial data from FLAURA2 on osimertinib plus chemotherapy in patients with EGFR-mutated advanced lung cancer.
EP. 4: Updates from MARIPOSA Trial in EGFR+ NSCLC
An overview of recent data from the MARIPOSA trial investigating amivantamab plus lazertinib in patients with EGFR-positive advanced lung cancer.
EP. 5: Treatment Decision-Making for Patients With EGFR+ NSCLC
An expert on EGFR+ non–small cell lung cancer discusses factors that influence treatment decisions.
EP. 6: PAPILLON: Amivantamab Plus Chemotherapy in Patients With NSCLC Positive for EGFR Mutations
Expert insights on the treatment of patients with non–small cell lung cancer positive for EGFR mutations and what the PAPILLON study seeks to address.
EP. 7: Key Takeaways on Treating Patients With EGFR+ NSCLC
Joshua K. Sabari, MD, offers key takeaways on treating patients with EGFR+ non–small cell lung cancer, highlighting the safety profile.
2 Commerce Drive Cranbury, NJ 08512